Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 4;8(2):rkae028.
doi: 10.1093/rap/rkae028. eCollection 2024.

Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey

Akira Yoshida  1 , Yuan Li  2 , Vahed Maroufy  2 , Masataka Kuwana  1 , Syahrul Sazliyana Shaharir  3 , Ashima Makol  4 , Parikshit Sen  5 , James B Lilleker  6   7 , Vishwesh Agarwal  8 , Esha Kadam  9 , Phonpen Akawatcharangura Goo  10 , Jessica Day  11   12   13 , Marcin Milchert  14 , Yi-Ming Chen  15 , Dzifa Dey  16 , Tsvetelina Velikova  17 , Sreoshy Saha  18 , Abraham Edgar Gracia-Ramos  19 , Ioannis Parodis  20   21 , Elena Nikiphorou  22   23 , Ai Lyn Tan  24   25 , Arvind Nune  26 , Lorenzo Cavagna  27 , Carlos Enrique Toro Gutiérrez  28 , Carlo Vinicio Caballero-Uribe  29 , Miguel A Saavedra  30 , Samuel Katsuyuki Shinjo  31 , Nelly Ziade  32   33 , Lina El Kibbi  34 , Johannes Knitza  35 , Oliver Distler  36 , Hector Chinoy  37   38   39 , Vikas Agarwal  40 , Rohit Aggarwal  41 , Latika Gupta  37   42   43 ; COVAD Study Group
Collaborators, Affiliations

Impaired health-related quality of life in idiopathic inflammatory myopathies: a cross-sectional analysis from the COVAD-2 e-survey

Akira Yoshida et al. Rheumatol Adv Pract. .

Abstract

Objectives: To investigate health-related quality of life in patients with idiopathic inflammatory myopathies (IIMs) compared with those with non-IIM autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs) and without autoimmune diseases (controls) using Patient-Reported Outcome Measurement Information System (PROMIS) instrument data obtained from the second COVID-19 vaccination in autoimmune disease (COVAD-2) e-survey database.

Methods: Demographics, diagnosis, comorbidities, disease activity, treatments and PROMIS instrument data were analysed. Primary outcomes were PROMIS Global Physical Health (GPH) and Global Mental Health (GMH) scores. Factors affecting GPH and GMH scores in IIMs were identified using multivariable regression analysis.

Results: We analysed responses from 1582 IIM, 4700 non-IIM AIRD and 545 nrAID patients and 3675 controls gathered through 23 May 2022. The median GPH scores were the lowest in IIM and non-IIM AIRD patients {13 [interquartile range (IQR) 10-15] IIMs vs 13 [11-15] non-IIM AIRDs vs 15 [13-17] nrAIDs vs 17 [15-18] controls, P < 0.001}. The median GMH scores in IIM patients were also significantly lower compared with those without autoimmune diseases [13 (IQR 10-15) IIMs vs 15 (13-17) controls, P < 0.001]. Inclusion body myositis, comorbidities, active disease and glucocorticoid use were the determinants of lower GPH scores, whereas overlap myositis, interstitial lung disease, depression, active disease, lower PROMIS Physical Function 10a and higher PROMIS Fatigue 4a scores were associated with lower GMH scores in IIM patients.

Conclusion: Both physical and mental health are significantly impaired in IIM patients, particularly in those with comorbidities and increased fatigue, emphasizing the importance of patient-reported experiences and optimized multidisciplinary care to enhance well-being in people with IIMs.

Keywords: e-survey; myositis; patient-reported outcome measures; quality of life.

PubMed Disclaimer

Figures

Graphical Abstract
Graphical Abstract
Figure 1.
Figure 1.
Flow diagram of participant selection
Figure 2.
Figure 2.
Patient-reported outcomes in each disease group. The (A) PROMIS GPH score, (B) PROMIS GMH score, (C) PROMIS PF-10a score, (D) Pain VAS score and (E) PROMIS Fatigue 4a score were compared between disease groups. *P < 0.05, ***P < 0.001. N.S.: not significant; PF: physical function
Figure 3.
Figure 3.
Patient-reported outcomes stratified by IIM subtypes. (A) PROMIS GPH score, (B) PROMIS GMH score, (C) PROMIS PF-10a score, (D) Pain VAS score and (E) PROMIS Fatigue 4a score were stratified by IIM subtypes. PF: physical function
See this image and copyright information in PMC

References

    1. Dalakas MC. Inflammatory muscle diseases. N Engl J Med 2015;372:1734–47. - PubMed
    1. Lundberg IE, Fujimoto M, Vencovsky J. et al. Idiopathic inflammatory myopathies. Nat Rev Dis Primers 2021;7:86. - PubMed
    1. Lundberg IE, de Visser M, Werth VP.. Classification of myositis. Nat Rev Rheumatol 2018;14:269–78. - PubMed
    1. Aggarwal R, Rider LG, Ruperto N. et al.; International Myositis Assessment and Clinical Studies Group and the Paediatric Rheumatology International Trials Organisation. 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: an International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Ann Rheum Dis 2017;76:792–801. - PMC - PubMed
    1. DiRenzo D, Bingham CO 3rd, Mecoli CA.. Patient-Reported outcomes in adult idiopathic inflammatory myopathies. Curr Rheumatol Rep 2019;21:62. - PMC - PubMed